GENE - gtglabs.com Long-Term Liabilities to Capital

Genetic Technologies (GENE) aims to become the benchmark for preventive medicine by implementing polygenic risk scores for the early detection of cardiac pathologies and cancer. This price chart for shares on the GURU.Markets platform confirms that long-term debt stands at 0.02, while the company develops an AI environment for B2B insurance, creating high software switching costs. Low quotes already price in slow sales growth while awaiting mass demand for comprehensive genetics.

For Genetic Technologies (GENE), the balance between long-term liabilities and equity determines development sustainability under stringent FDA regulation. This metric measures the share of borrowed funds with a maturity exceeding one year relative to the company's asset value. Analyzing the long-term debt-to-equity ratio allows for an assessment of the enterprise's financial leverage. High certification costs for CLIA laboratories make this indicator critical for evaluating the debt load. The stability of the curve confirms the business's ability to maintain patent protection without the risk of default.